First results with THR-149, a bicyclic peptide inhibitor that targets plasma kallikrein, showed safety and efficacy in treating patients with diabetic macular edema, according to a specialist speaking at the virtual Euretina congress.
“THR-149 is a highly potent, selective and stable peptide developed by Oxurion in partnership with Bicycle Therapeutics. It targets a VEGF-independent pathway, and I truly hope it will be a new treatment modality available to us for treating DME patients, particularly those who don’t respond to anti-VEGF injections,” Francesco Bandello, MD,